Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TANZEUM is a GSK fusion protein injectable approved in 2014 for diabetes management. The fusion modality combines therapeutic mechanisms to enhance glycemic control. Patient population and specific mechanism require additional clinical context.
Peak
Product is in peak lifecycle stage with moderate competitive pressure (30%), suggesting stable team size and focus on market defense and optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
TANZEUM at peak lifecycle offers stable, established-product career roles focused on market defense and commercial optimization. Limited open job requisitions suggest tight team structure with lower turnover.
Brand ManagerMedical Science Liaison
Worked on TANZEUM at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.